|
1
|
Keshavan MS, Nasrallah HA and Tandon R:
Schizophrenia, ‘just the facts’ 6. Moving ahead with the
schizophrenia concept: From the elephant to the mouse. Schizophr
Res. 127:3–13. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Corena-McLeod M: Comparative pharmacology
of risperidone and paliperidone. Drugs R D. 15:163–174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Robinson DG, Gallego JA, John M, Petrides
G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, et
al: A randomized comparison of aripiprazole and risperidone for the
acute treatment of first-episode schizophrenia and related
disorders: 3-month outcomes. Schizophr Bull. 41:1227–1236. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Subotnik KL, Casaus LR, Ventura J, Luo JS,
Hellemann GS, Gretchen-Doorly D, Marder S and Nuechterlein KH:
Long-acting injectable risperidone for relapse prevention and
control of breakthrough symptoms after a recent first episode of
schizophrenia. A randomized clinical trial. JAMA Psychiatry.
72:822–829. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kumar V, Ahmad MA, Najmi AK and Akhtar M:
Effect of sarcosine (a glycine transport 1 inhibitor) and
risperidone (an atypical antipsychotic drug) on MK-801 induced
learning and memory deficits in rats. Drug Res (Stuttg). 66:11–17.
2016.PubMed/NCBI
|
|
6
|
Takekita Y, Koshikawa Y, Fabbri C, Sakai
S, Sunada N, Onohara A, Nishida K, Yoshimura M, Kato M, Serretti A
and Kinoshita T: Cognitive function and risperidone long-acting
injection vs. paliperidone palmitate in schizophrenia: a 6-month,
open-label, randomized, pilot trial. BMC Psychiatry. 16:1722016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Waterhouse EG and Xu B: New insights into
the role of brain-derived neurotrophic factor in synaptic
plasticity. Mol Cell Neurosci. 42:81–89. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pandya CD, Kutiyanawalla A and Pillai A:
BDNF-TrkB signaling and neuroprotection in schizophrenia. Asian J
Psychiatr. 6:22–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang TL: Effects of antipsychotics on the
BDNF in schizophrenia. Curr Med Chem. 20:345–350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li JT, Su Y, Yang Y, Feng Z, Huang R and
Si T: Effects of acute treatment of dizocilpine maleate on
locomotor activity, prepulse inhibition and object recognition
memory in rats. Chin J Psychiatry. 45:97–102. 2012.(In
Chinese).
|
|
11
|
Su Y, Si T, Zhou D, Guo C and Shu L:
Establishment of a schizophrenia mouse model of deficient
sensorimotor gating by MK-801. Chin J Nerv Ment Dis. 32:558–560.
2006.(In Chinese).
|
|
12
|
Li J, Su Y, Yang Y, Feng Y, Huang RH and
Si TM: The effects of low-dose MK-801 treatment on reference
memory, spatial working memory and reversal learning in rats. Chin
J Nerv Ment Dis. 37:261–265. 2011.(In Chinese).
|
|
13
|
Yang YJ, Li YK, Wang W, Wan JG, Yu B, Wang
MZ and Hu B: Small-molecule TrkB agonist 7,8-dihydroxyflavone
reverses cognitive and synaptic plasticity deficits in a rat model
of schizophrenia. Pharmacol Biochem Behav. 122:30–36. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim TW, Kang HS, Park JK, Lee SJ, Baek SB
and Kim CJ: Voluntary wheel running ameliorates symptoms of
MK-801-induced schizophrenia in mice. Mol Med Rep. 10:2924–2930.
2014.PubMed/NCBI
|
|
15
|
Su YA, Si TM, Zhou DF, Guo CM, Wang XD,
Yang Y, Shu L and Liang JH: Risperidone attenuates MK-801-induced
hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C
receptors. Eur J Pharmacol. 564:123–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Barker GR, Bird F, Alexander V and
Warburton EC: Recognition memory for objects, place, and temporal
order: a disconnection analysis of the role of the medial
prefrontal cortex and perirhinal cortex. J Neurosci. 27:2948–2957.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bevins RA and Besheer J: Object
recognition in rats and mice: a one-trial non-matching-to-sample
learning task to study ‘recognition memory’. Nat Protoc.
1:1306–1311. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lipina TV, Palomo V, Gil C, Martinez A and
Roder JC: Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as
antipsychotic and cognitive enhancer in C57BL/6J mice.
Neuropharmacology. 64:205–214. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nilsson M, Hansson S, Carlsson A and
Carlsson ML: Differential effects of the N-methyl-d-aspartate
receptor antagonist MK-801 on different stages of object
recognition memory in mice. Neuroscience. 149:123–130. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rogóż Z and Kamińska K: The effect of
combined treatment with escitalopram and risperidone on the
MK-801-induced changes in the object recognition test in mice.
Pharmacol Rep. 68:116–120. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Houthoofd SA, Morrens M and Sabbe BG:
Cognitive and psychomotor effects of risperidone in schizophrenia
and schizoaffective disorder. Clin Ther. 30:1565–1589. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hill XL, Richeri A and Scorza C: Measure
of anxiety-related behaviors and hippocampal BDNF levels associated
to the amnesic effect induced by MK-801 evaluated in the modified
elevated plus-maze in rats. Physiol Behav. 147:359–363. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu B, Wang X, Wei JX, Ni PY, Liang LH,
Zhao LS, Ma XH, Li T and Wang YC: Effect of risperidone on the
BDNF-TrkB signalling pathway in rat brain. Sichuan Da Xue Xue Bao
Yi Xue Ban. 46:528–532, 610. 2015.(In Chinese). PubMed/NCBI
|
